Predictors of HBsAg Seroclearance in HBeAg-negative Chronic Hepatitis B Patients Treated with Nucleotide Analogs Plus Polyethylene Glycol Interferon

Overview

Journal Front Med (Lausanne)

Date 2025 Jan 23

PMID 39845839

Authors

Yan Peng

Mingzhe Ma

Ting Liu

Wenmin He

Shutao Lin

Wa Zhong

Xiaohui Min

Affiliations

Soon will be listed here.

Abstract

Introduction: The minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen (HBsAg) clearance.

Methods: In order to find out the advantaged population, we retrospectively collected 122 CHB patients treated with NAs alone or NAs plus PEG-IFN for 48 weeks, who were admitted to Sun Yat-sen Memorial Hospital from 2019 to 2024.

Results: We found HBsAg clearance rate in NAs plus PEG-IFN group was 40.98%, which was significantly higher than that in the NAs group. Thus, NAs plus PEG-IFN therapy served as a relatively ideal regimen and the patients received combined treatment were then incorporated for further analysis for searching efficacy predictors. Through using univariate and multivariate analysis, we confirmed the predictive value of HBsAg, alanine aminotransferase (ALT) at week 24, and ALT change values from baseline to week 24. The area under the receiver operating characteristic (ROC) curve of each indicators ranged from 0.663 to 0.982.

Discussion: In conclusion, our study verified the clinical value of NAs plus PEG-IFN for treating CHB patients. Moreover, for the first time, we found ALT change values from baseline to week 24 (dALT2) could act as a novel independent clinical efficacy predictors in the forementioned population.

References

Wu F, Yang Y, Li M, Liu Y, Li Y, Wang W . Add-on pegylated interferon augments hepatitis B surface antigen clearance continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World J Gastroenterol. 2020; 26(13):1525-1539. PMC: 7152523. DOI: 10.3748/wjg.v26.i13.1525. View

Yao Z, Qiao Y, Li X, Chen J, Ding J, Bai L . Exosomes Exploit the Virus Entry Machinery and Pathway To Transmit Alpha Interferon-Induced Antiviral Activity. J Virol. 2018; 92(24). PMC: 6258946. DOI: 10.1128/JVI.01578-18. View

Yip T, Wong G, Chan H, Tse Y, Lam K, Lui G . HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2018; 70(3):361-370. DOI: 10.1016/j.jhep.2018.10.014. View

Broquetas T, Garcia-Retortillo M, Mico M, Canillas L, Puigvehi M, Canete N . Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol. 2020; 12(11):1076-1088. PMC: 7701972. DOI: 10.4254/wjh.v12.i11.1076. View

Hsu Y, Huang D, Nguyen M . Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023; 20(8):524-537. DOI: 10.1038/s41575-023-00760-9. View

Li S, Li H, Xiong Y, Liu F, Peng M, Zhang D . Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat. 2017; 24 Suppl 1:12-20. DOI: 10.1111/jvh.12755. View

Yang S, Zeng W, Zhang J, Lu F, Chang J, Guo J . Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?. Emerg Microbes Infect. 2021; 10(1):1545-1554. PMC: 8354158. DOI: 10.1080/22221751.2021.1952851. View

Ye J, Chen J . Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol. 2021; 12:733364. PMC: 8452902. DOI: 10.3389/fimmu.2021.733364. View

Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X . Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol. 2018; 6(1):1-10. PMC: 5862993. DOI: 10.14218/JCTH.2017.00073. View

10.

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

11.

Ren H, Huang Y . Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepat. 2019; 26 Suppl 1:5-31. DOI: 10.1111/jvh.13150. View

12.

Stadler D, Kachele M, Jones A, Hess J, Urban C, Schneider J . Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep. 2021; 22(6):e49568. PMC: 8183418. DOI: 10.15252/embr.201949568. View

13.

Liang K, Hsu C, Chang M, Chen Y, Lai M, Yeh C . Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis. 2015; 213(6):966-74. DOI: 10.1093/infdis/jiv547. View

14.

Piccolo P, Lenci I, Demelia L, Bandiera F, Piras M, Antonucci G . A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2009; 14(8):1165-74. DOI: 10.3851/IMP1466. View

15.

Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z . Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018; 18(10):1085-1094. DOI: 10.1080/14712598.2018.1518423. View

16.

Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J . Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014; 61(4):777-84. DOI: 10.1016/j.jhep.2014.05.044. View

17.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X . Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176):1221-8. PMC: 6309542. DOI: 10.1126/science.1243462. View

18.

Kim J, Ghosh A, Ayithan N, Romani S, Khanam A, Park J . Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep. 2020; 10(1):1835. PMC: 7000714. DOI: 10.1038/s41598-020-58870-2. View

19.

Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X . HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018; 6(1):25-34. PMC: 5862996. DOI: 10.14218/JCTH.2017.00072. View

20.

Li Y, Wang F, Zhou J, Li L, Song C, Chen E . Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence-Based Review on Emerging Clinical Data. Clin Pharmacol Ther. 2024; 116(2):295-303. DOI: 10.1002/cpt.3287. View